Relugolix vs. Leuprolide Effects on Castration Resistance-Free Survival from the Phase 3 HERO Study in Men with Advanced Prostate Cancer.

Saad, Fred; George, Daniel J; Cookson, Michael S; Saltzstein, Daniel R; Tutrone, Ronald; Bossi, Alberto; Brown, Bruce; Selby, Bryan; Lu, Sophia; Tombal, Bertrand; Shore, Neal D

Saad, Fred; George, Daniel J; Cookson, Michael S; Saltzstein, Daniel R; Tutrone, Ronald; Bossi, Alberto; Brown, Bruce; Selby, Bryan; Lu, Sophia; Tombal, Bertrand; Shore, Neal D.

Afiliação

Saad F; University of Montreal Hospital Centre, Montreal, QC H2X 3E4, Canada.
George DJ; Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, Durham, NC 27710, USA.
Cookson MS; Department of Urology, The University of Oklahoma Health Sciences Center, Oklahoma City, OK 73104, USA.
Saltzstein DR; Urology San Antonio, San Antonio, TX 78229, USA.
Tutrone R; Chesapeake Urology, Towson, MD 21204, USA.
Bossi A; Department of Radiation Oncology, Gustave Roussy Cancer Institute, 94805 Villejuif, France.
Brown B; Myovant Sciences, Inc., Brisbane, CA 94005, USA.
Selby B; Myovant Sciences, Inc., Brisbane, CA 94005, USA.
Lu S; Myovant Sciences, Inc., Brisbane, CA 94005, USA.
Tombal B; Institut de Recherche Clinique, Université Catholique de Louvain, B-1348 Brussels, Belgium.
Shore ND; Carolina Urologic Research Center, Myrtle Beach, SC 29572, USA.

Cancers (Basel) ; 15(19)2023 Oct 05.

Article em En | MEDLINE | ID: mdl-37835548

Palavras-chave

advanced prostate cancer; castration resistance-free survival; leuprolide; relugolix

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Cancers (Basel) Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Canadá

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google